PsiOxus Gets Good Data Against Cachexia

PsiOxus Therapeutics has posted topline data from a recently completed Phase II trial of MT-102 in cancer-related cachexia. The primary endpoint has been met, showing that patients treated with MT-102 during a 16-week period have greater weight gain when compared to placebo treated patients, and at the highest dose of MT-102 (10mg twice daily) the difference is statistically significant. The clinical study has thus demonstrated MT-102’s ability to halt the cycle of weight loss, weakness and fatigue of cachectic late stage cancer patients.

The multinational, randomized, double blind, placebo controlled clinical trial was undertaken to examine the effect of MT-102 in patients with cachexia due to underlying stage III and IV colon or lung cancer. Cachexia causes anabolic and catabolic imbalance that leads to tissue wasting, which in turn causes as much as 40% of all cancer deaths.

MT-102 is the dual action Anabolic Catabolic Transforming Agent (ACTA) also known as s-pindolol. It is a small molecule agent administered orally twice daily. Two previous phase I/II clinical studies have been conducted to demonstrate the safety profile of MT-102.